ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)2016
Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers.
Article in Journal of immunotherapy (Hagerstown, Md. : 1997), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 54 citations in OpenAlex.
- Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Trial
- Overexpression of cancer testis antigens in gastric cancer and their correlations with the patients' clinicopathological characteristics.BMC medical genomics · 2025Article
- NY-ESO-1 facilitates anoikis resistance and tumor metastasis by hijacking deubiquitinase OTUB1 to stabilize PP1α.Cell death & disease · 2025Article
- Magea13 attenuates myocardial injury in acute myocardial infarction by inhibiting the cAMP-PKA signaling pathway.Apoptosis : an international journal on programmed cell death · 2025Article
- Identification and validation of a novel autoantibody biomarker panel for differential diagnosis of pancreatic ductal adenocarcinoma.Frontiers in immunology · 2025Article
- T-Switch: A specificity-based engineering platform for developing safe and effective T cell therapeutics.Immunity · 2024Article
- Adoptive transfer of membrane-restricted IL-12-TCR T cells promotes antigen spreading and elimination of antigen-negative tumor variants.Journal for immunotherapy of cancer · 2024Article
- Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma.Experimental hematology & oncology · 2024Review
- Melanoma Antigen Family A (MAGE A) as Promising Biomarkers and Therapeutic Targets in Bladder Cancer.Cancers · 2024Review
- The role of the NY-ESO-1 in the prognosis of gastric cancer.Biomolecules & biomedicine · 2023Article
- Article
- Review
- Evolution by innovation as a driving force to improve TCR-T therapies.Frontiers in oncology · 2023Review
- Silencing of A-kinase anchor protein 4 inhibits the metastasis and growth of non-small cell lung cancer.Bioengineered · 2022Article
- HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma.Biomedicines · 2022Article
- Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma.Clinical & translational immunology · 2022Article
- Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity.Frontiers in oncology · 2022Review
- Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer.Frontiers in immunology · 2022Review
- On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy.Biosensors · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Melanoma-associated antigen-A (MAGE-A) and New York esophageal squamous cell cancer-1 (NY-ESO-1) are 2 cancer testis antigens (CTA) demonstrating potential for use in targeted immunotherapy. Clinical trials in melanoma and synovial sarcomas targeting these antigens in immune-based therapies have demonstrated durable tumor regression. Although protein expression of NY-ESO-1 has been assessed in a variety of cancer types, the expression of MAGE-A has not been studied in depth. In this study we analyzed MAGE-A and NY-ESO-1 expression in 314 melanoma specimens from 301 melanoma patients, 38 patients with squamous cell cancers and 111 patients with adenocarcinomas. Our results demonstrated higher expression of MAGE-A compared with NY-ESO-1 in melanomas (32% vs. 13%) and squamous cell carcinomas (45% vs. 7.9%), and higher expression of both CTAs in metastatic versus primary tumors. CTA expression in adenocarcinomas was low (MAGE-A: 10%, NY-ESO-1: 0.9%). In addition, we looked at concordance of expression among metastatic melanoma lesions within the same patient and found concordant expression in 38 of 47 patients for MAGE-A and 43 of 47 patients for NY-ESO-1. Our study demonstrated that the MAGE-A family may be of greater utility than NY-ESO-1 for targeted immunotherapy in a variety of cancer histologies, in particular metastatic melanomas and squamous cell carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.